Oguzhan Karatepe, Idris Kurtulus, Orcun Unal, Orhan Yalcin, Ahu Kemik, Gulcin Kamali, Gokhan Adas, Muharrem Battal, Mine Adas, Hale Ozgun and Murat Aksoy
Background: Erythropoietin (Epo), a hormone produced by the kidney that promotes the formation of red blood cells in the bone marrow, is considered anti-inflammatory,anti-apoptotic, angiogenetic and sitoprotective. In this study, high dose erythropoietin is examined on an animal model for ischemic colitis (IC) to detect its possible potential benefits. Methods: Thirty female Wistar albino rats weighing 250-300 g were randomized into three experimental groups as follows: in Group 1, animals were sham operated (n = 10) and received distilled water; in Groups 2 and 3, the rats underwent a standardized surgical procedure to induce IC (n = 10 in each group). Group 2 animals served as the controls, receiving only tap water, while Group 3 animals received 3000 IU/kg eritropoetin as a single high dose. All animals were sacrificed 72 h after devascularization. Colonic malondialdehyde (MDA) levels, glutathione (GSH), myeloperoxidase (MPO), and caspase 3 activities of the sacrified rats were measured. CD-34 was evaluated by the immunohistochemical examination of the colonic tissue. Results: Colonic ischemia significantly increased the colonic MDA levels, caspase 3 activity, and TNF alfa in comparison to the control group. Epo treatment was associated with increased GSH levels, decreased MDA, and caspase 3 activity. Histopathological examination revealed that the intestinal mucosal structure was preserved in the Epo treated group. Moreover, treatment with Epo significantly increased CD-34 (stem cell) when compared to the ischemic colitis group. Conclusion: Epo reduced colonic damage in ischemic colitis. The mechanism of the protection associated with Epo was due to its mobilization of the stem cells as well as its anti-apoptotic and anti-inflammatory effects.
இந்தக் கட்டுரையைப் பகிரவும்
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 